Health Discovery Corporation announced the successful clinical trial results for HDC's new molecular diagnostic test for prostate cancer licensed exclusively to Clarient, in which HDC will receive a 30 percent royalty based on reimbursements received by Clarient from third parties.
Health Discovery Corporation announces successful clinical trial results for new molecular diagnostic test for prostate cancer